Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Open access

Abstract

Ann Oncol 2017; 28: iv119–iv142 (doi:10.1093/annonc/mdx225) Under the section “Gastrointestinal toxicity: Gastrointestinal toxicity of anti-CTLA4 antibodies: Diagnosis” The sigmoid colon and the rectum are involved in most cases; therefore, a flexible sigmoidoscopy is generally sufficient to make the diagnosis of anti-CTLA4-induced enterocolitis [38]. Is replaced with: The sigmoid colon and the rectum are involved in most cases; therefore, a flexible sigmoidoscopy is generally sufficient to make the diagnosis of anti-CTLA4-induced enterocolitis [38, 42]. Under the section “Gastrointestinal toxicity: Gastrointestinal toxicity of anti-CTLA4 antibodies: Management” Overall, one-third to two-thirds of patients either do not respond to high-dose i.v. steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering. These patients require infliximab and usually have an excellent response. A single dose of infliximab (5mg/kg) is generally sufficient [18, 35, 36, 38]. Is replaced with: Overall, one-third to two-thirds of patients either do not respond to high-dose i.v. steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering [38, 42]. These patients require infliximab and usually have an excellent response. A single dose of infliximab (5mg/kg) is generally sufficient [18, 35, 36, 38, 42]. Figures The following changes apply as shown in the updated version below. In “Figure 8. ICPi-related toxicity: management of diarrhoea and colitis” Mild (G1): i.e. < 3 liquid stools per day over baseline, feeling well ICPi can be continued Is replaced with: Mild (G1): i.e. < 4 liquid stools per day over baseline, feeling well ICPi can be continued Severe (G3/4): i.e. > 6 liquid stools per day over baseline or if episodes within 1h of eating Requires hospitalisation and isolation until infection excluded ICPi to be withheld Is replaced with: Severe (G3/4): i.e. ≥ 7 liquid stools per day or life-threatening Requires hospitalisation and isolation until infection excluded ICPi to be withheld Below “Figure 9. ICPi-related toxicity: management of pneumonitis” Ab, antibody; Is replaced with: Ab, antibiotic; Under the section “Acknowledgements” We thank Prof. M. Gore and Dr L. Spain from the Royal Marsden Hospital, London, UK, for their help with developing the up-to-date AE management algorithms. Is replaced with: We thank Prof. M. Gore and Dr L. Spain from the Royal Marsden Hospital, London, UK, for their help with developing the up-to-date AE management algorithms. Dr Spain provided the irAE management algorithms for this article. Under the section “References” A new reference is added: 42. Verschuren EC, van den Eertwegh AJ, Wonders J et al. Clinical, endoscopic and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 2016; 14: 836–842. 49. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–384. Is replaced with: 50. Weber JS, Gibney G, Sullivan RJ et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943–955. September 2018 When the above changes were made, Figure 6 was accidentally replaced with Figure 8 in the original article. This has now been corrected back. The Publisher apologizes for the error. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 28PreviewImmunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 has become standard of care for an increasing number of indications (Table 1). Therefore, an increasing number of patients will be exposed to these drugs with a chance of developing toxicities from these treatments. Depending on the immune checkpoint that is targeted, the incidence of toxicity varies. Toxicities from immune checkpoint inhibitors (ICPis) can be divided into infusion reactions and immune-related adverse events (irAEs) or adverse events of special interest (AEoSI). Full-Text PDF Open Archive

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy162

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Cited by

See all 431

Metadata

Authors
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-10
Volume
29
Pages
iv264-iv266
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2999042597
Cited by
431
References
0
Citations by year
2026: 12 · 2025: 20 · 2024: 37 · 2023: 57 · 2022: 64 · 2021: 88 · 2020: 93 · 2019: 57 · 2018: 2
Type
journal article
Language
en
Open access
Licence
Locations
Annals of Oncology (publishedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
immunotherapy toxicity, immune checkpoint inhibitors, anti-CTLA-4 antibody, enterocolitis, gastrointestinal toxicity, infliximab, corticosteroids, diarrhea, colitis, immune-related adverse events, flexible sigmoidoscopy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1093/annonc/mdy162
The paper
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018). Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1093/annonc/mdy162

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.